In this study, we have shown that combined RT and TLR9 agonist administration has synergistic anti-tumor effect in mice bearing a murine lung adenocarcinoma with improved primary tumor growth retardation and reduction of systemic pulmonary metastases. The gene discussed is TLR9; the disease is neoplasm.